Precision Medicine for Coronary Plaque Phenotype Guided Cardiovascular Care

Abstract

Precision medicine has revolutionized the management of atherosclerotic cardiovascular disease by enabling individualized care based on coronary plaque phenotype. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, treatment strategies, and emerging therapies in plaque phenotype-guided cardiovascular care. We discuss the clinical implications of integrating advanced imaging modalities and biomarker profiling with therapeutic decision-making and summarize recent guideline recommendations that support this tailored approach. The article provides practical insights for clinicians seeking to optimize outcomes through mechanism-based, patient-specific interventions.

Introduction

Cardiovascular disease (CVD) remains the leading cause of mortality globally, with coronary artery disease (CAD) constituting a major portion of the disease burden. Traditional management of CAD has followed a 'one-size-fits-all' approach, primarily guided by risk factors and degree of stenosis. However, the recognition that coronary plaque morphology, composition, and biological activity profoundly influence clinical outcomes has catalyzed a shift toward precision medicine. By characterizing plaque phenotypes—ranging from stable fibrous plaques to rupture-prone lipid-rich and inflamed lesions—clinicians can more accurately predict acute coronary events and tailor therapies to individual risk profiles.

Epidemiology / Disease Burden

Atherosclerotic CAD accounts for approximately 17.9 million deaths annually worldwide, with a significant proportion attributable to acute coronary syndromes (ACS) precipitated by high-risk plaque. Population-based imaging studies reveal that subclinical vulnerable plaques are prevalent even among asymptomatic individuals, especially those with metabolic syndrome, diabetes, or familial hypercholesterolemia. The increasing prevalence of obesity and diabetes has contributed to a rise in the population at risk for high-burden, complex plaque phenotypes, underscoring the necessity for refined stratification tools and targeted interventions.

Pathophysiology

Coronary atherosclerosis is characterized by progressive lipid accumulation, inflammatory cell infiltration, and fibrous tissue remodeling within the arterial wall. Plaque phenotypes are classified based on structural and biological features—fibroatheromas with large necrotic cores and thin fibrous caps (thin-cap fibroatheroma, TCFA) are particularly prone to rupture, leading to thrombosis and myocardial infarction. In contrast, calcified or fibrous plaques are more stable but may cause ischemia via progressive luminal narrowing. Recent advances in molecular imaging have elucidated key mechanisms, such as endothelial dysfunction, macrophage-driven inflammation, and microcalcification, that govern plaque vulnerability and clinical behavior.

Risk Factors

Traditional risk factors including age, male sex, hypertension, hyperlipidemia, diabetes, and smoking remain central to CAD pathogenesis. However, specific factors contribute to adverse plaque phenotypes. Genetic predisposition (e.g., familial hypercholesterolemia), elevated lipoprotein(a), chronic inflammatory conditions (such as rheumatoid arthritis), and metabolic syndrome are strongly associated with greater necrotic core content, increased plaque inflammation, and higher propensity for rupture. Emerging evidence highlights the role of non-traditional factors, such as gut microbiota metabolites and clonal hematopoiesis, in modulating plaque phenotype and instability.

Clinical Features

While many individuals with high-risk plaque phenotypes remain asymptomatic until an acute event, certain features may suggest heightened risk. Patients with recurrent angina, rapidly progressive symptoms, or history of prior ACS are more likely to harbor vulnerable plaques. Biomarkers of inflammation (e.g., high-sensitivity C-reactive protein) and evidence of microvascular dysfunction may further indicate increased plaque activity. Importantly, conventional risk assessment tools may underestimate risk in patients with high-risk phenotypes, emphasizing the need for advanced diagnostic strategies.

Diagnosis

The advent of high-resolution coronary imaging has transformed the ability to characterize plaque phenotype in vivo. Intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near-infrared spectroscopy (NIRS) provide detailed assessment of plaque composition, cap thickness, lipid burden, and inflammatory infiltration. Coronary computed tomography angiography (CCTA) enables non-invasive identification of high-risk features such as positive remodeling, low attenuation plaque, and spotty calcification. Integration of imaging with circulating biomarkers—such as myeloperoxidase, matrix metalloproteinases, and microRNAs—enhances risk stratification and enables longitudinal monitoring of plaque biology.

Treatment & Management

Management of CAD in the context of plaque phenotype requires an individualized, mechanism-oriented approach. Statins remain the cornerstone of therapy, providing both lipid-lowering and anti-inflammatory benefits that stabilize high-risk plaques. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors further reduce LDL cholesterol and may regress lipid-rich plaques. In patients with elevated inflammation, agents targeting interleukin-1β (e.g., canakinumab) or colchicine have shown promise in reducing recurrent cardiovascular events. Antithrombotic strategies may be tailored based on plaque vulnerability, with more potent or prolonged therapy considered in patients with TCFA or recent ACS. Lifestyle interventions, including dietary modification and structured exercise, synergize with pharmacotherapy to reduce plaque progression and promote stabilization.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in both diagnostic and therapeutic domains. Artificial intelligence-driven analysis of coronary imaging allows automated identification of high-risk plaques and prediction of clinical events. Novel lipid-lowering agents (e.g., inclisiran, bempedoic acid) and anti-inflammatory drugs (e.g., ziltivekimab) are under investigation for their effects on plaque phenotype and event reduction. Plaque-targeted therapies, such as nanoparticle-based drug delivery and local photodynamic therapy, represent emerging frontiers in precision intervention. Ongoing clinical trials are evaluating the impact of population-wide screening for high-risk plaques and early intervention on long-term outcomes.

Guideline Recommendations

Contemporary guidelines from major cardiovascular societies recommend integration of plaque characterization into risk assessment for selected patient populations. The 2022 ACC/AHA guidelines endorse the use of CCTA for evaluation of stable chest pain and for identifying features of high-risk plaque in ambiguous cases. European guidelines emphasize the role of advanced imaging and aggressive risk factor modification in patients with evidence of vulnerable plaques. There is growing consensus that treatment intensity should be commensurate with plaque biology, not solely luminal stenosis or traditional risk score.

Conclusion

Plaque phenotype-guided precision medicine represents a paradigm shift in the management of coronary artery disease. Advanced imaging and biomarker profiling enable nuanced risk stratification and tailored therapeutic strategies that address the underlying pathobiology of atherosclerosis. As research continues to elucidate the mechanisms governing plaque vulnerability and therapeutic response, the integration of precision diagnostics and targeted therapies holds promise for improving cardiovascular outcomes in high-risk populations. Continued adoption of guideline-endorsed, phenotype-driven approaches will be essential in realizing the full potential of personalized cardiovascular care.